Riskpilot← Back to searchSign inGet full accessMetaboGen AB
ABDissolvedOrg 5568727142Research and experimental development on biotechnology · NACE 7211Est. 20116 employees
Revenue 2022
SEK 0
EBITDA margin
—
-8% vs 2021
Equity ratio
95.1%
Financial strength
Net profit 2022
SEK -14K
+65% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -10,4M | -8% |
| Net profit | SEK -14K | +65% |
| Total assets | SEK 28,1M | -3% |
| Equity | SEK 26,8M | +0% |
| Employees | 6 | — |
Legal name
MetaboGen AB
Org number
5568727142
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
21 november 2011
Share capital
SEK 89 000
Employees
6 (FTE)
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att på kommersiella grunder bedriva utveckling och marknadsföring av kvalificerade produkter och tjänster baserade på forskning inom området för tarmflorans påverkan på hälsan, utveckla och patentera nya idéer inom detta område, äga och förvalta värdepapper samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 1 557 | 1 983 | 989 | 1 046 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — |
| EBITDA | −3 240 | −4 186 | −3 546 | −4 535 | −6 838 | −9 618 | −9 587 | −10 362 |
| Depreciation & amort. | −0 | −81 | −119 | −144 | −275 | −425 | −453 | −688 |
| EBIT | −3 240 | −4 267 | −3 665 | −4 679 | −7 113 | −10 043 | −10 040 | −11 050 |
| Net financials | — | — | — | −12 | −3 | −6 | −8 | −13 |
| Profit before tax | −3 241 | −4 267 | −3 665 | −4 691 | 15 649 | −1 | −40 | −14 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −3 241 | −4 267 | −3 665 | −4 691 | 15 649 | −1 | −40 | −14 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 5 090 | 7 051 | 7 689 | 2 516 | 30 967 | 29 947 | 29 141 | 28 147 |
| Equity | 4 811 | 4 544 | 879 | −3 812 | 26 837 | 26 836 | 26 796 | 26 781 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 279 | 2 507 | 6 810 | 6 329 | 4 130 | 3 111 | 2 345 | 1 366 |
| Total debt | 279 | 2 507 | 6 810 | 6 329 | 4 130 | 3 111 | 2 345 | 1 366 |
EBITDA margin
-1036200000.0%
This company
15.8%
Market median
-6558227948% vs market
20152022
Equity ratio
95.1%
This company
38.2%
Market median
+149% vs market
20152022
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20152022
Net profit margin
-1400000.0%
This company
8.1%
Market median
-17284051% vs market
20152022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152022
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20152022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JM Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BioGaia AB | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BioGaia AB
MetaboGen AB Board members of MetaboGen AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jenny Matilda Holmgren | Chief Auditor | 0 companies |
| Isabelle Valerie G Ducellier | Board of Directors | 0 companies |
| Peter Michael Rothschild | Board of Directors | 0 companies |
| Gert Fredrik Bäckhed | Board of Directors | 0 companies |
| Alexander Kotsinas | Deputy Board Member | 0 companies |
| Bo Möllstam | Board of Directors | 0 companies |